2H-Indazole, 2-[(2-chloro-4-fluorophenyl)Methyl]-3-(4-fluorophenyl)-7-(trifluoroMethyl)-
2H-Indazole, 2-[(2-chloro-4-fluorophenyl)Methyl]-3-(4-fluorophenyl)-7-(trifluoroMethyl)- Basic information
- Product Name:
- 2H-Indazole, 2-[(2-chloro-4-fluorophenyl)Methyl]-3-(4-fluorophenyl)-7-(trifluoroMethyl)-
- Synonyms:
-
- 2H-Indazole, 2-[(2-chloro-4-fluorophenyl)Methyl]-3-(4-fluorophenyl)-7-(trifluoroMethyl)-
- LXR623
- 2-[(2-Chloro-4-fluorophenyl)methyl]-3-(4-fluorophenyl)-7-(trifluoromethyl)-2H-indazole
- WAY 252623
- 2-[(2-chloro-4-fluorophenyl)Methyl]-3-(4-fluorophenyl)-7-(trifluoroMethyl)-
- 2-[(2-Chloro-4-fluorophenyl)methyl]-3-(4-fluorophenyl)-7-(trifluoromethyl)-2H-indazole WAY 252623
- LXR623/LXR-623
- LXR-623 (WAY-252623)
- CAS:
- 875787-07-8
- MF:
- C21H12ClF5N2
- MW:
- 422.78
- Product Categories:
-
- Inhibitor
- Inhibitors
- API
- Mol File:
- 875787-07-8.mol
2H-Indazole, 2-[(2-chloro-4-fluorophenyl)Methyl]-3-(4-fluorophenyl)-7-(trifluoroMethyl)- Chemical Properties
- Melting point:
- 93℃
- Boiling point:
- 528.4±50.0 °C(Predicted)
- Density
- 1.40
- storage temp.
- room temp
- solubility
- DMSO:50.0(Max Conc. mg/mL);118.26(Max Conc. mM)
Ethanol:52.0(Max Conc. mg/mL);123.0(Max Conc. mM) - pka
- -1.87±0.30(Predicted)
- form
- powder
- color
- white to beige
- InChI
- 1S/C21H12ClF5N2/c22-18-10-15(24)9-6-13(18)11-29-20(12-4-7-14(23)8-5-12)16-2-1-3-17(19(16)28-29)21(25,26)27/h1-10H,11H2
- InChIKey
- KYWWJENKIMRJBI-UHFFFAOYSA-N
- SMILES
- FC(F)(F)c1c2n[n](c(c2ccc1)c4ccc(cc4)F)Cc3c(cc(cc3)F)Cl
2H-Indazole, 2-[(2-chloro-4-fluorophenyl)Methyl]-3-(4-fluorophenyl)-7-(trifluoroMethyl)- Usage And Synthesis
Uses
WAY 252623 is a novel and potent LXR (liverX receptor) β-agonist used as a potential candidate for the treatment of atopic dermatitis.
Biochem/physiol Actions
WAY-252623 (LXR623) is an orally available, potent and highly selective Liver X receptors (LXRs) agonist that significantly reduced total and LDL-cholesterol. WAY-252623 reduces lesion progression in the murine LDLR(-/-) atherosclerosis model.
in vivo
LXR-623 (400 mg/kg, p.o.) crosses the blood-brain barrier, induces target gene expression, and achieves therapeutic levels in GBM cells in the brain with minimal activity in the periphery. LXR-623 inhibits tumor growth, promotes tumor cell death, and prolongs the survival of mice bearing intracranial patient-derived GBMs[1]. LXR-623 (1.5, 5 mg/kg/day) significantly reduces progression of atherosclerosis in animals compared with the placebo group[2]. WAY-252623 (15 and 50 mg/kg) results in a significant reduction of atherosclerosis in a dose-dependent manner. WAY-252623 (20, 60, and 120 mg/kg/day, p.o.) displays neutral lipid effects in this CETP-expressing Syrian hamster[3]. Moreover, LXR-623 (50 mg/kg) induces gene expression in rodent peripheral blood cells in rat. LXR-623 (0, 15 and 50 mg/kg) dose-dependently upregulates transcription of ABCA1 and ABCG1 in monkey whole blood cells proportional to dose[4].
storage
Store at +4°C
2H-Indazole, 2-[(2-chloro-4-fluorophenyl)Methyl]-3-(4-fluorophenyl)-7-(trifluoroMethyl)-Supplier
- Tel
- sales@boylechem.com
- Tel
- 021-64968085,64968086-5815,5812; 13472757003
- xiaoxia.zeng@rainbowpharma.cn
- Tel
- 0411-62910999 13889544652
- sales@meilune.com
- Tel
- +86057186818502 13588463833
- info@sagechem.com
- Tel
- 021-58950125
- info@chemexpress.com